Several case reports describe the use of MAD [8,9,21,22], and Amalou and coworkers [10] evaluated the effectiveness of MAD in 10 patients with GLUT1DS: Epilepsy improved in all patients, and movement disorders also enhanced. Here, SLC2A1 is linked to epilepsy.